BusinessPeregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred StockBy Nasdaq OMXMar 7, 2016, 9:05 PM UTC
BusinessPeregrine Pharmaceuticals Announces Formal Commissioning of New, State-of-the-Art Commercial Manufacturing FacilityBy Nasdaq OMXMar 7, 2016, 1:05 PM UTC
BusinessPeregrine to Report Financial Results for Third Quarter of Fiscal Year 2016 Prior to Market Open on March 9, 2016By Nasdaq OMXMar 3, 2016, 9:05 PM UTC
BusinessIntrommune Therapeutics Announces Issuance of U.S. Patent Covering Oral Mucosal Immunotherapy for Food AllergyBy Nasdaq OMXMar 1, 2016, 12:10 PM UTC
BusinessPeregrine Pharmaceuticals Provides Update on Phase III SUNRISE Trial of BavituximabBy Nasdaq OMXFeb 25, 2016, 9:05 PM UTC
BusinessIntrommune Therapeutics to Present at New York Venture Capital Association 2016 Health & Bio Technology SummitBy Nasdaq OMXFeb 22, 2016, 12:15 PM UTC
BusinessFate Therapeutics to Present Preclinical Data for ProTmune™ at 2016 BMT Tandem MeetingsBy Nasdaq OMXFeb 21, 2016, 1:01 PM UTC
BusinessHuman Validation Data Supporting Saronic Biotechnology’s Lead Therapeutic SBI1997 Published in the Journal of ImmunotherapyBy Nasdaq OMXFeb 9, 2016, 4:11 PM UTC
